Announcement Under Irish Takeover Rules Relevant Securities In Issue
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “
Company”) confirms that, as of the close of
business on June 13, 2014, the Company’s issued share capital, excluding...
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “ Company”) confirms that, as of the close of business on June 13, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 451,177,675 ordinary shares, par value US$0.20 per share (the “ Ordinary Shares”). The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29. The Company confirms that, as of the close of business on June 13, 2014, there were outstanding 1,733,112 restricted share units (the “ Restricted Share Units”) and 14,103,872 options to purchase Ordinary Shares (the “ Share Options”) granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price. The Company also confirms that, as of the close of business on June 13, 2014, there were outstanding performance share units (the “ Performance Share Units”) entitling holders to receive up to a maximum of 2,196,116 Ordinary Shares upon vesting, assuming satisfaction of the applicable performance criteria at maximum performance. About Covidien Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business. The number of Ordinary Shares capable of being issued in respect of the Restricted Share Units and Performance Share Units described in this announcement includes the Ordinary Shares capable of being issued upon the vesting of the applicable dividend equivalent units attaching to the respective Restricted Share Units and Performance Share Units.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.